Frankfurt - Delayed Quote EUR
BioArctic AB (publ) (B9A.F)
At close: 9:14 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
299,346.00
615,995.00
228,291.00
23,146.00
62,347.00
Cost of Revenue
82,667.00
89,627.00
74,326.00
55,067.00
50,242.00
Gross Profit
216,679.00
526,368.00
153,965.00
-31,921.00
12,105.00
Operating Expense
308,375.00
269,409.00
161,903.00
107,932.00
94,423.00
Operating Income
-91,696.00
256,959.00
-7,938.00
-139,853.00
-82,318.00
Net Non Operating Interest Income Expense
45,044.00
33,849.00
1,785.00
-983.00
-1,091.00
Pretax Income
-60,975.00
276,485.00
-11,167.00
-140,511.00
-86,691.00
Tax Provision
27,306.00
47,237.00
11.00
-20,723.00
-18,174.00
Net Income Common Stockholders
-88,280.00
229,249.00
-11,179.00
-119,789.00
-68,517.00
Diluted NI Available to Com Stockholders
-88,280.00
229,249.00
-11,179.00
-119,789.00
-68,517.00
Basic EPS
-1.00
2.60
-0.13
-1.36
-0.78
Diluted EPS
-1.00
2.59
-0.13
-1.36
-0.78
Basic Average Shares
88,147.94
88,230.64
88,074.30
88,059.99
88,059.99
Diluted Average Shares
88,200.37
88,487.40
88,682.99
88,579.99
88,181.99
Total Operating Income as Reported
-96,015.00
252,640.00
-17,336.00
-139,723.00
-85,012.00
Total Expenses
391,042.00
359,036.00
236,229.00
162,999.00
144,665.00
Net Income from Continuing & Discontinued Operation
-88,280.00
229,249.00
-11,179.00
-119,789.00
-68,517.00
Normalized Income
-88,280.00
229,249.00
-11,179.00
-119,782.18
-68,351.89
Interest Income
44,463.00
34,228.00
2,535.00
--
7.00
Interest Expense
-632.00
328.00
559.00
838.00
984.00
Net Interest Income
45,044.00
33,849.00
1,785.00
-983.00
-1,091.00
EBIT
-61,607.00
276,813.00
-10,608.00
-139,673.00
-85,707.00
EBITDA
-61,607.00
295,241.00
4,025.00
-126,566.00
-74,694.00
Reconciled Cost of Revenue
82,667.00
89,627.00
74,326.00
55,067.00
50,242.00
Reconciled Depreciation
--
7,439.00
14,184.00
13,045.00
10,920.00
Net Income from Continuing Operation Net Minority Interest
-88,280.00
229,249.00
-11,179.00
-119,789.00
-68,517.00
Total Unusual Items Excluding Goodwill
--
--
--
-8.00
-209.00
Total Unusual Items
--
--
--
-8.00
-209.00
Normalized EBITDA
-61,607.00
295,241.00
4,025.00
-126,558.00
-74,485.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
-1.18
-43.89
12/31/2020 - 11/2/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
9926.HK Akeso, Inc.
66.350
-0.97%
1801.HK INNOVENT BIO
37.450
-1.83%
NCNA NuCana plc
1.5000
-1.32%
LGND Ligand Pharmaceuticals Incorporated
129.90
+11.12%
CUE Cue Biopharma, Inc.
1.7800
+7.88%
CELZ Creative Medical Technology Holdings, Inc.
3.1600
0.00%
HRMY Harmony Biosciences Holdings, Inc.
34.91
+1.81%
VRCA Verrica Pharmaceuticals Inc.
0.7043
-5.63%
INSM Insmed Incorporated
71.69
-1.61%
JAZZ Jazz Pharmaceuticals plc
119.08
+6.75%